http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2804594-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3386f5906dc1bdc9c934203594712c66 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-0102 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2408 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2465 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2434 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-47 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-24 |
| filingDate | 2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_087aac357023c5f807206181a345f748 |
| publicationDate | 2021-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2804594-T3 |
| titleOfInvention | Chemical crosslinkers |
| abstract | A method of making a modified lysosomal targeting peptide comprising: a. contacting variant insulin-like growth factor 2 (vIGF2) with a bifunctional crosslinking agent to introduce a protected hydrazide group at the N-terminal residue; b. deprotecting hydrazide modified vIGF2 in solution to form deprotected hydrazide modified vIGF2; c. contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; d. binding at least one deprotected hydrazide-modified vIGF2 to the lysosomal enzyme; wherein: vIGF2 comprises one or more of the following changes compared to the wild-type human IGF2 sequence: removal of N-terminal amino acid residues 1-4; glutamic acid residue at position 6 of arginine substituted wild-type human IGF2; wild-type human IGF 2 tyrosine residue at position 27 substituted with leucine; lysine residue at position 65 of arginine substituted human IGF-2; the bifunctional crosslinking agent comprises acetone, dimethylbenzyloxycarbonyl, trimethylbenzyloxycarbonyl protected hydrazide groups or any combination thereof; or the bifunctional crosslinking agent comprises N-tert-butoxycarbonyl (tBoc) protected hydrazide crosslinker (NHS-PEG4-tBoc-hydrazide), methoxybenzyloxycarbonyl (BOM) protected hydrazide (NHS-PEG4-BOM-hydrazide), NHS-PEG4- acetone protected hydrazide, NHS-PEG4- dimethylbenzylcarbonyl protected hydrazide, trimethylbenzyloxycarbonyl protected NHS-PEG4-hydrazide; or a crosslinker of formula: ** (See formula) ** or any combination thereof. |
| priorityDate | 2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 221.